LABORATORY INVESTIGATION- HUMAN/ANIMAL TISSUE Protein

Temozolomide (TMZ) is the standard chemotherapeutic agent for human malignant glioma, but intrinsic or acquired chemoresistance represents a major obstacle to successful treatment of this highly lethal group of tumours. Obtaining better understanding of the molecular mechanisms underlying TMZ resistance in malignant glioma is important for the development of better treatment strategies. We have successfully established a passage control line (D54-C10) and resistant variants (D54-P5 and D54-P10) from the parental TMZ-sensitive malignant glioma cell line D54-C0. The resistant sub-cell lines showed alterations in cell morphology, enhanced cell adhesion, increased migration capacities, and cell cycle arrests. Proteomic analysis identified a set of proteins that showed gradual changes in expression according to their 50% inhibitory concentration (IC50). Successful validation was provided by transcript profiling in another malignant glioma cell line U87-MG and its resistant counterparts. Moreover, three of the identified proteins (vimentin, cathepsin D and prolyl 4-hydroxylase, beta polypeptide) were confirmed to be upregulated in high-grade glioma. Our data suggest that acquired TMZ resistance in human malignant glioma is associated with promotion of malignant phenotypes, and our reported molecular candidates may serve not only as markers of chemoresistance but also as potential therapeutic targets in the treatment of TMZ-resistant human malignant glioma, providing a platform for future investigations.

[1]  M. Schuhmann,et al.  Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  F. Westermann,et al.  Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. , 2008, Carcinogenesis.

[3]  D. Fortin,et al.  La barrière hémato-encéphalique : un facteur clé en Neuro-oncologie , 2004 .

[4]  J. Yates,et al.  Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. , 2011, Journal of proteome research.

[5]  M. Sanson,et al.  Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line , 2006, Molecular Cancer Therapeutics.

[6]  S. Finkelstein,et al.  Multifaceted resistance of gliomas to temozolomide. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Weil,et al.  Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers , 2006, Neurology.

[8]  P. Wen,et al.  Glioma Therapy in Adults , 2006, The neurologist.

[9]  F. Gallyas,et al.  TIP47 protects mitochondrial membrane integrity and inhibits oxidative‐stress‐induced cell death , 2010, FEBS letters.

[10]  R. McLendon,et al.  Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma , 2008, Clinical Cancer Research.

[11]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[12]  M. Di Michele,et al.  Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin. , 2010, International journal of oncology.

[13]  V. Petrozza,et al.  Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell , 2010, Modern Pathology.

[14]  M. Rudolph,et al.  TIP47 functions in the biogenesis of lipid droplets , 2009, The Journal of cell biology.

[15]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[16]  K. Stein,et al.  Temozolomide for high grade glioma. , 2008, The Cochrane database of systematic reviews.

[17]  G. Stamp,et al.  Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl‐2 transfected DU145 prostatic cancer cells , 2001, The Journal of pathology.

[18]  O. Carpén,et al.  Src Phosphorylates Ezrin at Tyrosine 477 and Induces a Phosphospecific Association between Ezrin and a Kelch-Repeat Protein Family Member* , 2005, Journal of Biological Chemistry.

[19]  J. Nevins,et al.  Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma , 2009, Clinical Cancer Research.

[20]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  M. Dolan,et al.  Temozolomide: realizing the promise and potential , 2003, Current opinion in oncology.

[22]  J. Sarkaria,et al.  Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain* , 2010, The Journal of Biological Chemistry.

[23]  M. Berger,et al.  Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. , 2005, Cancer research.

[24]  F. Gallyas,et al.  TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G. , 2010, European journal of cell biology.

[25]  G. Berchem,et al.  Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis , 2002, Oncogene.

[26]  H. Schild,et al.  Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment , 2008, Amino Acids.

[27]  Ioan Tabus,et al.  Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays , 2006, Proteomics.

[28]  J. Luk,et al.  Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat‐shock proteins (Hsp27, Hsp70, GRP78) up‐regulation and their associated prognostic values , 2006, Proteomics.

[29]  Gianluca Bontempi,et al.  Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. , 2010, Neoplasia.

[30]  N. Seki,et al.  Cathepsin D is a potential serum marker for poor prognosis in glioma patients. , 2005, Cancer research.

[31]  M. Berger,et al.  p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. , 2001, Cancer research.

[32]  F. Howe,et al.  Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. , 2008, Clinical chemistry.

[33]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[34]  J. Luk,et al.  Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (, 2010, Journal of proteome research.

[35]  Karen H. Almeida,et al.  The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. , 2005, Cancer research.

[36]  Qiang Sun,et al.  Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol , 2011, Journal of Cancer Research and Clinical Oncology.

[37]  Ron Orlando,et al.  Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. , 2008, Cancer letters.

[38]  Philip J Day,et al.  Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. , 2010, Journal of proteome research.

[39]  W. Mason.  Emerging drugs for malignant glioma. , 2008, Expert opinion on emerging drugs.

[40]  S. Niclou,et al.  Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.

[41]  M. Berger,et al.  Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. , 2001, Cancer research.

[42]  M. Savio,et al.  Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. , 2010, Mutation research.

[43]  M. Tate,et al.  Biology of angiogenesis and invasion in glioma , 2009, Neurotherapeutics.

[44]  Connie R. Jimenez,et al.  iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype* , 2009, Molecular & Cellular Proteomics.

[45]  Timothy C Ryken,et al.  Management of malignant glioma: steady progress with multimodal approaches. , 2006, Neurosurgical focus.

[46]  D. Fortin.  [The blood-brain barrier should not be underestimated in neuro-oncology]. , 2004, Revue neurologique.

[47]  S. Keir,et al.  Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. , 1997, Cancer research.

[48]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[49]  R. Bjerkvig,et al.  Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. , 2006, Cancer research.

[50]  A. Määttä,et al.  Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. , 2007, Biochemical and biophysical research communications.

[51]  X. Bian,et al.  Unique proteomic features induced by a potential antiglioma agent, Nordy (dl‐nordihydroguaiaretic acid), in glioma cells , 2008, Proteomics.